ARO-ALK7
NCT06937203
Arrowhead · Phase 1/2 · Recruiting · Enrollment 150
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part 1 and Part 2 (optional cohort): ARO-ALK7 | Population n/r | n/r | n/r | n/r | n/r |
| Part 1 and Part 2 (optional cohort): Placebo | Population n/r | n/r | n/r | n/r | n/r |
| Part:2: ARO-ALK7 + Tirzepatide | Population n/r | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | Population n/r | n/r | n/r | n/r | n/r |